United Therapeutics Corporation (UTHR)
NASDAQ: UTHR · Real-Time Price · USD
317.40
-2.97 (-0.93%)
May 30, 2025, 3:17 PM - Market open
United Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 2,994 | 2,877 | 2,328 | 1,936 | 1,686 | 1,483 | Upgrade
|
| Revenue | 2,994 | 2,877 | 2,328 | 1,936 | 1,686 | 1,483 | Upgrade
|
| Revenue Growth (YoY) | 19.84% | 23.63% | 20.20% | 14.88% | 13.63% | 2.38% | Upgrade
|
| Cost of Revenue | 329.3 | 309.7 | 257.5 | 151.6 | 122.5 | 108.1 | Upgrade
|
| Gross Profit | 2,665 | 2,568 | 2,070 | 1,785 | 1,563 | 1,375 | Upgrade
|
| Selling, General & Admin | 666.1 | 640.4 | 476 | 472.8 | 466.1 | 421.1 | Upgrade
|
| Research & Development | 525.9 | 481 | 408 | 322.9 | 410 | 357.7 | Upgrade
|
| Operating Expenses | 1,187 | 1,121 | 884 | 795.7 | 876.1 | 778.8 | Upgrade
|
| Operating Income | 1,478 | 1,446 | 1,186 | 989 | 686.9 | 596.4 | Upgrade
|
| Interest Expense | -35.7 | -42.9 | -59.3 | -32.4 | -18.6 | -23.5 | Upgrade
|
| Interest & Investment Income | 196.4 | 199.1 | 162.7 | 45.2 | 16.7 | 28.6 | Upgrade
|
| Other Non Operating Income (Expenses) | -1.4 | -1.4 | -27.3 | -38.3 | 43.8 | 26.4 | Upgrade
|
| EBT Excluding Unusual Items | 1,637 | 1,601 | 1,262 | 963.5 | 728.8 | 627.9 | Upgrade
|
| Gain (Loss) on Sale of Investments | -1.9 | 9 | 15.8 | -1.7 | -2.3 | 16.4 | Upgrade
|
| Asset Writedown | - | - | -3.6 | -11.2 | -132.6 | -5.4 | Upgrade
|
| Legal Settlements | -71.1 | -71.1 | - | - | - | - | Upgrade
|
| Pretax Income | 1,564 | 1,539 | 1,274 | 950.6 | 593.9 | 638.9 | Upgrade
|
| Income Tax Expense | 353.2 | 343.9 | 289.5 | 223.3 | 118.1 | 124.1 | Upgrade
|
| Net Income | 1,211 | 1,195 | 984.8 | 727.3 | 475.8 | 514.8 | Upgrade
|
| Net Income to Common | 1,211 | 1,195 | 984.8 | 727.3 | 475.8 | 514.8 | Upgrade
|
| Net Income Growth | 15.25% | 21.36% | 35.41% | 52.86% | -7.58% | - | Upgrade
|
| Shares Outstanding (Basic) | 45 | 45 | 47 | 46 | 45 | 44 | Upgrade
|
| Shares Outstanding (Diluted) | 48 | 49 | 50 | 49 | 47 | 45 | Upgrade
|
| Shares Change (YoY) | -3.02% | -2.41% | 2.47% | 2.54% | 6.05% | 1.83% | Upgrade
|
| EPS (Basic) | 27.10 | 26.44 | 21.04 | 15.98 | 10.60 | 11.65 | Upgrade
|
| EPS (Diluted) | 25.10 | 24.64 | 19.81 | 15.00 | 10.06 | 11.54 | Upgrade
|
| EPS Growth | 18.87% | 24.38% | 32.07% | 49.10% | -12.83% | - | Upgrade
|
| Free Cash Flow | 1,129 | 1,081 | 747.6 | 663.7 | 477.4 | 696.4 | Upgrade
|
| Free Cash Flow Per Share | 23.40 | 22.28 | 15.04 | 13.69 | 10.09 | 15.61 | Upgrade
|
| Gross Margin | 89.00% | 89.24% | 88.94% | 92.17% | 92.73% | 92.71% | Upgrade
|
| Operating Margin | 49.35% | 50.26% | 50.96% | 51.08% | 40.75% | 40.21% | Upgrade
|
| Profit Margin | 40.44% | 41.53% | 42.31% | 37.56% | 28.23% | 34.71% | Upgrade
|
| Free Cash Flow Margin | 37.69% | 37.55% | 32.12% | 34.28% | 28.32% | 46.95% | Upgrade
|
| EBITDA | 1,555 | 1,519 | 1,239 | 1,040 | 736.8 | 646.3 | Upgrade
|
| EBITDA Margin | 51.93% | 52.78% | 53.24% | 53.73% | 43.71% | 43.57% | Upgrade
|
| D&A For EBITDA | 77.3 | 72.5 | 53.2 | 51.3 | 49.9 | 49.9 | Upgrade
|
| EBIT | 1,478 | 1,446 | 1,186 | 989 | 686.9 | 596.4 | Upgrade
|
| EBIT Margin | 49.35% | 50.26% | 50.96% | 51.08% | 40.75% | 40.21% | Upgrade
|
| Effective Tax Rate | 22.59% | 22.35% | 22.72% | 23.49% | 19.89% | 19.42% | Upgrade
|
Updated Apr 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.